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Introduction
Avian pathogenic Escherichia coli (APEC) is a major reason
for a number of extraintestinal diseases in broiler chickens, in-
cluding colisepticemia, air sacculitis, pericarditis and perihep-
atitis (Howell, 1996; kariyawasam et al., 2004). These case
conditions can lead to huge economic losses to the poultry
industry each year as a result of increased percentages of low
weights, carcass condemnation in processing plants, and in-
creased number of mortalities among affected birds (Dziva
and Stevens, 2008). There are many serogroups of E. coli are
considered pathogenic commonly isolated O1, O2, O78, O8,
and O35, that can cause the previous conditions (Bélanger et
al., 2011; La Ragione and Woodward, 2002).
E. coli infections are controlled mainly by shielding birds
against major respiratory pathogens, as Newcastle Disease
(ND), Infectious Bronchitis (IB), Mycoplasmosis and immuno-
suppressive viral infections, Infectious Bursal Disease (IBD) and
Chicken Anemia (CA). In addition to the methods that are es-
sential for minimizing environmental stress (temperature im-
balance, improper ventilation, mycotoxins, and contaminated
drinking water), which all help to the incidence of E. coli infec-
tion (Shane, 2009).
Among the methods for controlling E. coli–associated dis-
eases, vaccines have received extra focusing because antimi-
crobials have faced partial success due to the generated
resistance to the existing antimicrobial agents and the lack of
new effective agents. 
The control of E. coli infections has been mostly depended
on vaccination with killed autologous bacterins (Trampel and
Griffith, 1997), but these deliberate short-lived serotype-spe-
cific protection and their usefulness is hindered by the differ-
ent serovars of E. coli could infect poultry. So, the use of live
vaccines was emerged, which require a low-cost in their prepa-
ration and their easiness in administration as well as their cross
protection efficacy. Vaccines depend on the defined genetic
deletion m.os. may be preferable candidates for live vaccines,
especially if it cannot revert to wild type. A number of re-
searchers have described attempts to develop live attenuated
vaccines for avian E. coli targeting several genes to develop
genetically defined mutants and none have emerged as suc-
*Corresponding author: Moemen A. Mohamed
E-mail address: moemenassiut@hotmail.com
Journal of Advanced Veterinary Research Volume 6, Issue 3 (2016) 89-92
Journal of Advanced Veterinary Research
http://advetresearch.com/index.php/avr/index
Poultry Diseases Department, Faculty of Veterinary Medicine, Assiut University 71515, Assiut, Egypt
ABSTRACT
ISSN: 2090-6277/2090-6269/ © 2016 JAVR. All rights reserved.
Evaluation of The Living Escherichia coli-O78 Deleted aroA Vaccine
Against Homologous and Heterologous E. coli Challenge in Broiler
Chickens
Moemen A. Mohamed*, Bakhit M. Bakhit, Awad A. Ibrahim, Mohamed Saleh
To determine whether the immunization using commercially available living Escherichia coli-
O78 aroA deleted vaccine (Poulvac®E. coli) is protective against APEC challenges or not.
Ninety chicks were divided into six groups (15 birds/each); two groups were vaccinated at
day 1 by spray and drinking routes then challenged intratracheally with homologous E. coli
O78 at day 21, the other two groups were similar to the previously mentioned groups but
challenged with heterologous E. coli O1 in parallel with the four challenged-vaccinated
groups there were two positive control (challenged-not vaccinated) groups; one challenged
with O78 and the other one with O1 at day 21 using intratacheal route. The best obtained
results were recorded to the vaccinated-challenged group with the homologous strain and
vaccinated by spraying method which exhibited decreases in organ lesion scores in com-
parison to the other groups (non-vaccinated challenged chickens and groups of chickens
either homologous challenged-vaccinated through drinking water or heterologous chal-
lenged-vaccinated groups). These findings suggest that vaccine is a suitable for minimizing
lesion scores against homologous challenge using spraying method that could lead to min-
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cessful commercial vaccines for colibacillosis in chickens or
turkeys (Peighambari and Gyles, 1998; Roland et al., 1999;
Peighambari et al., 2002; Roland et al., 2004). 
The aroA gene is responsible for the biosynthesis of aro-
matic amino acids (phenylalanine, tryptophan, and tyrosine)
in the virulent E. coli parent strain. Aromatic biosynthetic
(aroA) mutants (Hoiseth and Stocker, 1981) have unique ad-
vantage that the surface appendages, such as fimbriae and
flagella that have showed their importance in the pathogen-
esis of avian colibacillosis are still expressed. When the aroA
gene is deleted, the candidate E. coli becomes avirulent and
unable to continue in growth due to losing the capability to
synthesize the amino acids necessary for its existence.
The manufacturer of E. coli aroA-live vaccine has proved
that the produced vaccine protects chickens against the ho-
mologous and heterologous serogroups of E. coli. In contrary,
this vaccine has never been confirmed to have the efficacy in
protection against wild E. coli serotype O78 isolated from Thai-
land (Chansiripornchai, 2009).
Due to the previously mentioned debates among the ef-
ficacy of this vaccine and the wide use of antimicrobial agents
in the Egyptian poultry farms and the rapid increase of micro-
bial resistance to these agents. Our study designed to evaluate
this commercial living E. coli vaccine (Poulvac®E. coli) to show
its efficacy in minimizing the percentages of morbidity, mor-
tality and lesion scores among the challenged chickens that
may lead to decrease the economic losses facing owners that
is coming from purchasing antimicrobial agents and shorten-




Ninety, unvaccinated broiler chickens (Ross) of mixed sex
were obtained on the day of hatching from a commercial
hatchery. The chickens were fed ad libitum with commercial
diets suitable for their age has no antibacterial or anticoccidial
components, before and during the experiments. Vaccination
against diseases other than E. coli was applied using vaccines
of different manufacturers and included Newcastle Disease
vaccines (Hitchner B1 and LaSota vaccines were applied by eye
drop route at 7 and 17 days of age, respectively), and Infec-
tious Bursal Disease vaccine (live intermediate vaccine was ap-
plied by eye drop route at 13 days of age).
Vaccine
E. coli aroA vaccine (Poulvac®E. coli, Pfizer Animal Health,
Exton, PA 19341, USA). The vaccine dosages were calculated
according to a titer of 7.0 x107CFU per dose in 0.5 ml for spray
application, the size of the droplets was adjusted to 100 ± 10
µm by means of cold fogger (ULV Fogger SFYM-YM02B,
Saintfine®), and in 5 ml for drinking water application.
Challenge
Challenged strains were APEC O78 and O1 that had been
originally isolated from heart blood of chickens with a field
case of colisepticemia from farms at different localities in
Egypt. For preparation of bacterial suspensions, the bacterial
strains were inoculated into brain heart infusion broth and in-
cubated at 37oC for 18 hours. Then, bacterial cells were har-
vested by centrifugation at 5000 rpm for 30 minutes and
washed thrice with PBS and resuspended in PBS to yield an
approximate concentration of 6 x 108 CFU/ml. Each chicken
was challenged with 1 ml of the inocula by intratracheal route.
After challenge, all birds were observed daily for a week; any
bird that died during the observation period was necropsied.
The surviving chickens at the end of the experiment were all
euthanatized, necropsied, and examined for colibacillosis le-
sions.
Assessment of protection against homologous challenge
Forty five chickens were divided into 3 groups of 15 each.
Chickens in groups 1 and 2 were vaccinated at one day of age
with Poulvac®E. coli vaccine by coarse spray and drinking
water routes, respectively. Chickens in group 3 were not vac-
cinated and kept as positive control. Since the onset of immu-
nity for Poulvac®E. coli is demonstrated to be 14 days post
vaccination (CVMP, 2012), chickens in all groups were chal-
lenged at 21 days of age with APEC O78.
Assessment of protection against heterologous challenge
Forty five chickens were divided into 3 groups of 15 each.
Chickens in groups 4 and 5 were vaccinated at one day of age
with Poulvac®E. coli vaccine by coarse spray and drinking
water routes, respectively. Chickens in group 6 were not vac-
cinated and kept as positive control. Chickens in all groups
were challenged at 21 days of age with APEC O1.
Evaluation criteria
Individual body weights in grams were recorded at 10, 20,
24 and 28 days of age using sensitive scale (Five grams differ-
ence sensitivity). Mortalities were recorded as the number of
chickens that had died before the end of the experiment.
Scores for gross pathologic findings were assigned according
to data from (Peighambari et al., 2002) as follows: air sacs (nor-
mal = 0, mild cloudiness and thickness = 1, moderate cloudi-
ness and thickness accompanied by serous exudate or fibrin
spots = 2, extensive cloudiness and thickness accompanied
by muco- or fibrinopurulent exudate = 3), heart and peri-
cardium (normal = 0, turbid with excessive or cloudy fluid in
the pericardial cavity = 1, marked pericarditis = 2), and liver
(normal = 0, slight amount of fibrinous exudate = 1, marked
perihepatitis = 2).
Statistical analysis
Analysis of mortalities in different groups was performed
by Chi-square test. ANOVA and Duncan multiple range tests
were used for the statistical comparison of the body weights




No adverse events (death or clinical signs) potentially at-
tributable to the vaccine were observed. The weight gain of
the chickens during the first three weeks of life showed that
there was no negative effect because of vaccination.
Protection against homologous challenge
Regarding mortalities and average body weights, there
were no significant differences between the studied groups.
For the gross pathological findings, the average lesion scores
of air sacs and the pericardium in the group vaccinated with
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Poulvac®E. coli by coarse spray but not by drinking water
route were statistically significantly less than those of the pos-
itive control group (Table 1).
Protection against heterologous challenge
Mortalities, average body weights, and average lesion
scores did not differ significantly between the studied groups
(Table 2).
Discussion
A vaccine containing a ΔaroA mutant of an O78:K80 E. coli
is currently marketed by Zoetis (Poulvac®E. coli, Zoetis). In this
study, we evaluated the protective ability of this vaccine by
spray and drinking methods against homologous (E. coli O78)
and heterologous infections (E. coli O1) in broiler chickens.
The obtained results showed, there were no unfavorable
reactions (death or other clinical signs) attributable to the ad-
ministration of the vaccine, an indication of its safety for mass
administration.
The weight gain of the chickens (Table1 and 2) during the
first three weeks of life, before the birds being challenged with
APEC, showed that there was no negative effect because of
vaccination, as there were no significant differences between
vaccinated and control groups, similar results were obtained
by Salehi et al. 2012 and Mombarg et al. 2014, unlike Filho et
al. (2013), who reported that, there was a tendency of increase
on the weight of the control group during the second week
and with significant difference during the third week post vac-
cination in comparison to the vaccinated groups.
Also, from the gained results, there were statistical signif-
icant differences in minimizing lesions score of heart (peri-
cardium) and air sacs between the vaccinated groups with
homologous challenge using spray method (Table 1). In con-
trast, no statistical significant results were obvious in the other
groups either by homologous using drinking water method
and heterologous challenges vaccinated using either routes
(Table 1 and 2). This efficacy of spray method in reducing the
lesion scores may be due to the living bacteria that delivered
by spray, allowing stimulation of eye, conjunctiva, and
bronchus-associated lymphoid tissues (Peighambari and
Gyles, 1998; kariyawasam et al., 2004; Chansiripornchai, 2009).
Several research articles were comparable to the results of
our study, which mentioned that vaccination against E. coli in-
fection is not fully successful in chicken protection (Chaffer et
al., 1997; Peighambari et al., 2002; Amoako et al., 2004; Salehi
et al., 2012) may be for the mentioned reasons; firstly, this
could be due to the existence of a maternally derived antibod-
ies, even if they are present in little levels (Elazab et al., 2009).
Secondly, Lynne et al. (2006) observed that the vaccination
with Iss protein encouraged protection against E. coli infection
in chickens, while in our research, it is probable that the used
vaccine did not live lengthy enough in the organs of chickens
to express a suitable amount of Iss protein. Thirdly, may be
due to administration of single dose of the vaccine when birds
are still immunologically immature at one day old so may be
a need for another shot to induce the immunity (Heller et al.,
1990; Sadeyen et al., 2015). Fourthly, may be the size of
sprayer droplet, in the present study the size of sprayer
droplets that used with tested vaccine were about 100 µm,
which were larger in their size than those used in the studies
of Kariyawasam et al. (2004) and La ragione et al. (2013). These
large droplets can’t reach deeply in the respiratory tract to in-
duce a strong immune response as happened when used a
small droplet size that can move to the lower parts of the res-
piratory tract.
In the present study, the vaccination in drinking water
proved its failure to protect chickens against challenging with
E. coli that may be due to the chickens need high number of
E. coli (1010CFU/ml) as proposed by DuPont et al. 1970 and
Amoako et al. 2004). 
In concern to the failure of vaccine to protect against het-
erologous challenge was in parallel with previous studies (Deb
and Harry, 1976; Peighambari, et al., 2002; Kariyawasam et al.,
2004) that traced this to role of LPS in relationship with pro-
tection during vaccination with live E. coli vaccine.
On reverse to our results, La Ragione et al. (2013) stated
that the aroA construct was shown to be successful as a vac-
cine against colibacillosis in chickens and turkeys caused by a
homologous APEC O78 and also against an untypeable APEC
strain in chickens. Also, Sadeyen et al. (2015) verified that the
two vaccines (Poulvac®E. coli and a formalin-inactivated vac-
Table 1. Mortalities, average body weights and lesion scores of groups in the protection study against homologous challenge
a, bThe superscripts that differed in each column have significantly different at confidential 95% (p≤0.05)
* Group 1: Poulvac®E. coli/Coarse spray/Challenged O78; Group 2: Poulvac®E. coli/Drinking water/Challenged O78; Group 3: Not vaccinated/Challenged
O78
Table 2. Mortalities, average body weights and lesion scores of groups in the protection study against heterologous challenge
a, bThe superscripts that differed in each column have significantly different at confidential 95% (p≤0.05)
* Group 4: Poulvac®E. coli/Coarse spray/Challenged O1; Group 5: Poulvac®E. coli/Drinking water/Challenged O1; Group 6: Not vacci-
nated/Challenged O1
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cine) were protective against homologous intra-air sac chal-
lenge with E. coli in turkeys.
Conclusion
The living Escherichia coli-O78 deleted aroA vaccine effec-
tive in reducing the lesion scores against homologous infec-
tion by using the spray method that may lead to decrease the
downgrading carcasses and condemnation rate, but could not
protect against homologous infection when the vaccine was
used in drinking water as well as heterologous infected-vac-
cinated groups. Based on the results of the current study, fur-
ther investigations may be required to determine the factors
that may play a role in the efficacy of this vaccine.
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